Beta Bionics (BBNX) risk factors, FY2024 10-K

Risks Related to Our Limited Commercial History, Financial Position and Need for Additional Capital

1. 01We have a limited commercial history and limited experience marketing and selling our products. We only recently launched our commercial product, which may make it difficult to evaluate the prospects for our future viability and predict our future performance
2. 02We have incurred significant operating losses since inception and cannot assure you that we will be able to achieve or sustain profitability
3. 03Our quarterly and annual financial condition, operating results and cash flows may fluctuate in the future, which could cause the market price of our stock to decline substantially
4. 04general economic, political, industry and market conditions
5. 05We currently rely on sales of our iLet and related single-use products to generate all of our revenue, and any factors that negatively impact sales of these products may adversely affect our business, financial condition and operating results
6. 06claims that any of our products, or any component thereof, infringes on patent rights or other intellectual property rights of third parties
7. 07Although we consummated our initial public offering and the concurrent private placement, we may need to raise additional funds in the future, and these funds may not be available on acceptable terms, if at all
8. 08the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims
9. 09Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in our initial public offering, restrict our operations or require us to relinquish rights to our technologies or iLet

Risks Related to Our Business, Strategy and Industry

1. 10The failure of our iLet and related products to achieve and maintain market acceptance could result in us achieving sales below our expectations, which would cause our business, financial condition and operating results to be materially and adversely affected
2. 11results of clinical trials relating to our existing product or product candidates or to similar competitive products
3. 12The market opportunities for our iLet for the treatment of diabetes may be smaller than we anticipated, limiting our ability to successfully sell our current and future products
4. 13We face competition from numerous competitors, most of whom have far greater resources than we have, which may make it more difficult for us to achieve significant market penetration and which may allow them to develop additional products for the treatment of diabetes that compete with our iLet
5. 14Our results of operations will be harmed if we are unable to accurately forecast customer demand for our products and manage our inventory
6. 15Competing products, therapeutic techniques or other technological developments and breakthroughs for the monitoring, treatment or prevention of diabetes may render our products obsolete or less desirable
7. 16There can be no assurance that we will be able to successfully expand our distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or in other jurisdictions for which we are able to obtain regulatory clearance
8. 17We will need to expand our organization, and we may experience challenges in managing this growth as we build our capabilities, which could disrupt our operations
9. 18Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel
10. 19We may acquire other companies or technologies, which could fail to result in a commercial product or revenue, divert our management’s attention, result in additional dilution to our stockholders and otherwise disrupt our business
11. 20If we were to be sued for product liability, we could face substantial liabilities that exceed our resources, limit sales of our iLet and limit commercialization of any products that we may develop
12. 21termination of existing agreements by our partners and potential partners failing to partner with us
13. 22Risks Related to the Development, Regulatory Approval and Commercialization of our iLet Bionic Pancreas and Product Candidates
14. 23enforcing and defending intellectual property rights and claims
15. 24the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval
16. 25Clinical trials are expensive, time-consuming, difficult to design and implement, and have an uncertain outcome. Further, we may encounter substantial delays in our clinical trials
17. 26Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing authorization or clearance
18. 27lack of adequate funding to continue the clinical trial
19. 28Interim, “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
20. 29Unacceptable safety concerns caused by our commercial or development-stage products could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label, or the delay or denial of required marketing authorizations or clearances
21. 30we could face decreased demand for our products as a result of PWD, caregivers and HCPs losing confidence in our products
22. 31We are developing our iLet in combination with other therapies and devices, which requires additional development time and exposes us to additional risks
23. 32Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products from being developed, authorized or commercialized in a timely manner, which could negatively impact our business
24. 33Our long-term growth depends, in part, on our ability to develop and enhance the iLet, expand our indications and commercialize the iLet in a timely manner. If we fail to do so we may be unable to grow our business or compete effectively
25. 34receive adequate coverage and reimbursement for procedures performed with the iLet
26. 35ability to achieve and maintain market share and increase our revenue, which could have a material adverse effect on our business, financial condition and results of operations

Risks Related to Reimbursement and Pricing

1. 36Coverage and reimbursement may be limited or unavailable in certain market segments for our iLet, which could make it difficult for us to sell any investigational devices profitably
2. 37neither experimental nor investigational
3. 38We are working with payors to establish coverage and reimbursement under both the DME and PBP channels as we believe that this strategy increases access and optimizes the potential for better medical outcomes for PWD through the adoption of the iLet
4. 39If we experience pricing pressure for our products and we are unable to reduce our expenses, including the per unit cost of producing our products, there may be a material adverse effect on our business, financial condition, results of operations and cash flows
5. 40Healthcare reform measures could hinder or prevent the commercial success of our solutions

Risks Related to Manufacturing and Our Reliance on Third Parties

1. 41which would have a material adverse impact on our business, financial condition and results of operations, negatively impact our ability to compete and cause the price of our common stock to decline
2. 42collaboration agreements may restrict our right to independently pursue new investigational devices
3. 43We have limited experience manufacturing our products and, if we are unable to manufacture our products in high-quality commercial quantities successfully and consistently to meet demand, our growth will be limited
4. 44potential damage to or destruction of our manufacturing equipment or manufacturing facilities
5. 45We obtain some of the components and subassemblies included in our iLet from single source suppliers, and the partial or complete loss of one or more of these suppliers could cause significant production delays, an inability to meet customer demand and a substantial loss in revenue
6. 46we may not be able to quickly establish additional or replacement suppliers, particularly for our single source components
7. 47legal actions by our customers
8. 48Performance issues, service interruptions or price increases by our shipping carriers could negatively affect our business, financial condition and results of operations and harm our reputation and our customer relationships
9. 49We may enter into collaborations, licensing arrangements, joint ventures, strategic alliances or partnerships with third parties that may not result in the development of commercially viable products or the generation of significant future revenues
10. 50If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies
11. 51We rely and will continue to rely on third parties to conduct clinical trials of our iLet, which means we do not have full control over the conduct of such trials

Risks Related to Government Regulation

1. 52We and our suppliers are subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to penalties if we fail to comply with applicable regulatory requirements
2. 53Our iLet or any of its components may be subject to product recalls in the future. A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our iLet, could have a significant adverse impact on us
3. 54Additional federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers
4. 55The distribution of products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products
5. 56Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security

Risks Related to Our Intellectual Property

1. 57If we are unable to obtain or protect intellectual property rights related to the iLet, we may not be able to compete effectively in our market
2. 58covering technology that we have in-licensed from BU and Xeris. Therefore, these patents and patent applications may not be prosecuted and enforced in a manner consistent with the best interests of our business
3. 59If we fail to comply with our obligations in our current and future intellectual property licenses with third parties, we could lose rights, which may be important to our business
4. 60Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our future patents
5. 61We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful
6. 62We may be unsuccessful in licensing or acquiring intellectual property from third parties that may be required to develop and commercialize our product candidates
7. 63Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our products
8. 64The intellectual property or technology licensed from various third parties may be subject to retained rights
9. 65Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business
10. 66We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties
11. 67We may be subject to claims challenging the inventorship or ownership of our future patents and other intellectual property
12. 68We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties
13. 69Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed to others
14. 70We may enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world
15. 71Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
16. 72The terms of our patents may not be sufficiently long to effectively protect our products and business
17. 73If we are not successful in obtaining patent term extensions for our future products, our business may be harmed
18. 74Any trademarks we have obtained or may obtain may be infringed or otherwise violated, or successfully challenged, resulting in harm to our business
19. 75Intellectual property rights do not necessarily address all potential threats to our competitive advantage

Risks Related to Ownership of Our Common Stock

1. 76The trading price of our common stock may be volatile, and you could lose all or part of your investment
2. 77changes in accounting principles
3. 78Our executive officers, directors and principal stockholders, if they choose to act together, continue to have the ability to control or significantly influence all matters submitted to stockholders for approval
4. 79A significant portion of our total outstanding shares are eligible to be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well
5. 80Future sales and issuances of our securities, including pursuant to our equity incentive plans, may cause dilution to our stockholders or decrease our stock price
6. 81capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder
7. 82We are an emerging growth company and a smaller reporting company, and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors
8. 83In addition, the JOBS Act allows us as an “emerging growth company” to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies
9. 84Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, would be your sole source of gain
10. 85Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock
11. 86provide that special meetings of our stockholders may be called only by the Chairman of the board, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors
12. 87resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions
13. 88Adverse changes in general economic conditions in the United States and outside of the United States could adversely affect us
14. 89Our ability to use our net operating loss (NOL) carryforwards and certain other tax attributes may be limited
15. 90We may be subject to adverse legislative or regulatory changes in tax laws, and there are uncertainties in the interpretation and application of existing, new and proposed tax laws and regulations, any of which could materially affect our tax obligations and effective tax rate
16. 91We and our directors and executive officers may be subject to litigation for a variety of claims, which could harm our reputation and adversely affect our business, results of operations and financial condition
17. 92Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
18. 93We could be subject to securities class action litigation
19. 94If securities or industry analysts cease to publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
20. 95Our insurance policies may be inadequate, may not cover all of our potential liabilities and may potentially expose us to unrecoverable risks
21. 96We or the third parties upon whom we depend may be adversely affected by earthquakes, fires or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
22. 97Evolving expectations around corporate responsibility practices, specifically related to environmental, social and governance (ESG) matters, may expose us to reputational and other risks
23. 98Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of operations